EBI-907

• Description:

  EBI-907 is an orally active and highly potent B-RafV600E inhibitor. EBI-907 demonstrates excellent A375 and Colo-205 cellular antiproliferative activity with IC50 values of 13 nM and 14 nM, respectively. EBI-907 can also cause tumor regression in a B-RafV600E-dependent Colo-205 tumor xenograft model of mice. EBI-907 is promising for research of melanoma and B-RafV600E associated cancers[1][2].

• UNSPSC:

  12352005

• Target:

  Raf

• Type:

  Reference compound

• Related Pathways:

  MAPK/ERK Pathway

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ebi-907.html

• Smiles:

  O=S(NC1=CC=C(C(C2=CC3=CNC4=NN=C(C5CC5)C4=C3C=C2OC)=C1Cl)F)(CCCF)=O

• Molecular Formula:

  C23H21ClF2N4O3S

• Molecular Weight:

  506.95

• References & Citations:

  [1]Lu B, et al. Discovery of EBI-907: A highly potent and orally active B-Raf (V600E) inhibitor for the treatment of melanoma and associated cancers. Bioorg Med Chem Lett. 2016 Feb 1;26 (3) :819-823. |[2]Zhang J, et al. EBI-907, a novel BRAF (V600E) inhibitor, has potent oral anti-tumor activity and a broad kinase selectivity profile. Cancer Biol Ther. 2016;17 (2) :199-207.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [1581764-31-9]